ETS transcription factors: Multifaceted players from cancer progression to tumor immunity

Biochim Biophys Acta Rev Cancer. 2023 May;1878(3):188872. doi: 10.1016/j.bbcan.2023.188872. Epub 2023 Feb 24.

Abstract

The E26 transformation specific (ETS) family comprises 28 transcription factors, the majority of which are involved in tumor initiation and development. Serving as a group of functionally heterogeneous gene regulators, ETS factors possess a structurally conserved DNA-binding domain. As one of the most prominent families of transcription factors that control diverse cellular functions, ETS activation is modulated by multiple intracellular signaling pathways and post-translational modifications. Disturbances in ETS activity often lead to abnormal changes in oncogenicity, including cancer cell survival, growth, proliferation, metastasis, genetic instability, cell metabolism, and tumor immunity. This review systematically addresses the basics and advances in studying ETS factors, from their tumor relevance to clinical translational utility, with a particular focus on elucidating the role of ETS family in tumor immunity, aiming to decipher the vital role and clinical potential of regulation of ETS factors in the cancer field.

Keywords: E26 transformation specific; Transcription factor; Treatment; Tumor immune microenvironment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA-Binding Proteins / genetics
  • Humans
  • Neoplasms* / genetics
  • Neoplasms* / pathology
  • Proto-Oncogene Proteins c-ets / genetics
  • Proto-Oncogene Proteins c-ets / metabolism
  • Signal Transduction / genetics
  • Transcription Factors* / genetics

Substances

  • Transcription Factors
  • DNA-Binding Proteins
  • Proto-Oncogene Proteins c-ets